IOVANCE BIOTHERAPEUTICS, INC. Accounts Payable
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Accounts Payable of $26.21 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $26.21M.
- 2026-03-31: Accounts Payable, Current $37.45M.
- 2025-12-31: Accounts Payable, Current $22.16M.
- 2025-09-30: Accounts Payable, Current $31.24M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $26.21M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $37.45M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $22.16M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $31.24M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $32.00M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $28.49M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $27.51M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $31.69M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $20.42M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $25.70M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $33.12M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $19.27M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $31.16M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $31.57M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $26.60M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $24.25M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $20.01M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $20.45M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $27.38M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $12.18M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $21.91M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $13.37M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $13.51M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $24.79M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $10.24M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $10.61M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $15.57M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $9.92M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $12.78M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $7.59M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $2.74M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $6.01M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $5.20M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $6.58M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $1.23M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $2.90M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $3.69M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $2.17M 10-Q · filed 2017-05-03 | |
| 2016-12-31 | $863.00K 10-K · filed 2018-03-12 | |
| 2016-09-30 | $228.00K 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $725.00K 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $1.05M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $958.00K 10-K · filed 2017-03-09 | |
| 2015-09-30 | $1.16M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $1.16M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $1.11M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $1.25M 10-K · filed 2016-03-11 | $1.25M 10-K · filed 2015-03-16 |
| 2014-09-30 | $573.80K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $440.55K 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $286.32K 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $412.98K 10-K · filed 2015-03-16 | |
| 2013-09-30 | $1.55M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $1.48M 10-Q · filed 2013-10-23 | |
| 2013-03-31 | $1.29M 10-Q · filed 2013-10-23 | |
| 2012-12-31 | $1.10M 10-K · filed 2014-03-28 | |
| 2012-09-30 | $841.62K 10-Q · filed 2013-01-25 | |
| 2012-06-30 | $609.27K 10-Q/A · filed 2012-09-10 | |
| 2012-03-31 | $504.25K 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $190.05K 10-K · filed 2013-09-23 | |
| 2011-09-30 | $206.86K 10-Q · filed 2011-11-21 | |
| 2011-06-30 | $130.64K 10-Q/A · filed 2011-09-01 | |
| 2010-12-31 | $30.29K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |